Preclinical and clinical profile of Emmelle (dextrin-2-sulfate) - A potential anti-HIV microbicide

Journal of Applied Research

Volumn 5, Issue 1, 2005, Pages 26-34

  D'Cruz, Osmond J ^a,b   Uckun, Fatih M ^a  

^a PARKER HUGHES INSTITUTE   (United States)

^b Paradigm Pharmaceuticals   (United States)

Author keywords

Clinical trials; HIV AIDS; Intrarectal; Intravaginal; Topical microbicide

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DEXTRIN; DEXTRIN 2 SULFATE; EMMELLE; UNCLASSIFIED DRUG;

AFRICA; ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; EUROPE; GENITAL TRACT INFLAMMATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; SEXUAL TRANSMISSION; VIRUS CELL INTERACTION;

EID: 17044377659     PISSN: 1537064X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. United Nations Program on HIV/AIDS. Report on global HIV/AIDS epidemic. December 2003. Available at: http://www.unaids.org. Accessed March 1, 2005.
2. National Institute of Allergy and Infectious Diseases Fact Sheet: HIV Infection in Women. May 2004. Available at: http://www.niaid.nih.gov/factsheets/ women-hiv.htm. Accessed March 1, 2005.
3. D'Cruz OJ, Uckun FM. Clinical development of microbicides for the prevention of HIV infection. Curr Pharm Des. 2004;10:315-336.
4. Turpin JA. Considerations and development of topical microbicides to inhibit the sexual transmission of HIV. Expert Opin Investig Drugs. 2002;11:1077-1097.
5. The Alliance for Microbicide Development, Silver Spring, MD. Available at: http://www.microbicide.org/. Accessed March 1, 2005.
6. Brown D. Study finds drug-resistant HIV in half of infected patients. Washington Post. December 19, 2001. Available at: http://www.aegis.com/news/ads/ 2001/AD012196.html. Accessed March 1, 2005.
7. Susman E. Many HIV patients carry mutated drug-resistant strains. Lancet. 2002;359:49.
8. Quayle AJ, Xu C, Mayer KH, Anderson DJ. T lymphocytes and macrophages, but not motile spermatozoa, are a significant source of human immunodeficiency virus in semen. J Infect Dis. 1997;176:960-968.
9. Royce RA, Sena A, Gates W JR, Cohen MS. Sexual transmission of HIV. N Engl J Med. 1997;336:1072-1078.
10. Wright TC Jr, Subbarao S, Ellerbrock TV, et al. Human immunodeficiency virus 1 expression in the female genital tract in association with cervical inflammation and ulceration. Am J Obstet Gynecol. 2001;184:279-285.
11. Miller CJ, Shattock RJ. Target cells in vaginal HIV transmission. Microbes Infect. 2003;5:59-67.
12. Rowland-Jones SL. HIV: the deadly passenger in dendritic cells. Curr Biol. 1999;9:R248-R250.
13. Smith PD, Li L, Meng G. Mucosal events in the pathogenesis of human immunodeficiency virus type 1 infection. J Infect Dis. 1999;179(suppl 3):S436-S440.
14. Nobile C, Moris A, Porrot F, Sol-Foulon N, Schwartz O. Inhibition of human immunodeficiency virus type 1 env-mediated fusion by DC-SIGN. J Virol. 2003;77:5313-5323.
15. Pohlmann S, Doms RW. Evaluation of current approaches to inhibit HIV entry. Curr Drug Targets Infect Disord. 2002;2:9-16.
16. O'Hara BM, Olson WC. HIV entry inhibitors in clinical development. Curr Opin Pharmacol. 2002;2:523-528.
17. Starr-Spires LD, Collman RG. HIV-1 entry and entry inhibitors as therapeutic agents. Clin Lab Med. 2002;22:681-701.
18. De Clercq E. New anti-HIV agents and targets. Med Res Rev. 2002;22:531-565.
19. Ketas TJ, Frank I, Klasse PJ, et al. Human immunodeficiency virus type 1 attachment, coreceptor, and fusion inhibitors are active against both direct and trans infection of primary cells. J Virol. 2003;77:2762-2767.
20. Simmons G, Reeves JD, Hibbitts S, et al. Coreceptor use by HIV and inhibition of HIV infection by chemokine receptor ligands. Immunol Rev. 2000;177:112-126.
21. Chan DC, Kim PS. HIV entry and its inhibition. Cell. 1998;93:681-684.
22. Gallo SA, Finnegan CM, Viard M, et al. The HIV Env-mediated fusion reaction. Biochim Biophys Acta. 2003;1614:36-50.
23. Davies DS, inventor; ML Laboratories (Liverpool, GB3). Dextrin sulfates as anti HIV-1 agents and composition thereof. US Patent 5,439,892. August 8, 1995.
24. Baba M, Snoeck R, Pauwels R, De Clercq E. Sulfated polysaccharides are potent and selective inhibitors of various enveloped viruses, including herpes simplex virus, cytomegalovirus, vesicular stomatitis virus, and human immunodeficiency virus. Antimicrob Agents Chemother. 1988;32:1742-1745.
25. Ito M, Baba M, Sato A, Pauwels R, De Clercq E, Shigeta S. Inhibitory effect of dextrin sulfate and heparin on the replication of human immunodeficiency virus (HIV) in vitro. Antiviral Res. 1987;7:361-367.
26. Bagasra O, Lischner HW Activity of dextran sulfate and other polyanionic polysaccharides against human immunodeficiency virus. J Infect Dis. 1988;158:1084-1087.
27. Mitsuya H, Looney DJ, Kuno S, Ueno R, Wong-Staal F, Broder S. Dextran sulfate suppression of viruses in the HIV family: inhibition of virion binding to CD4+ cells. Science. 1988;240:646-649.
28. Baba M, Pauwels R, Balzarini J, Arnout J, Desmyter J, De Clercq E. Mechanism of inhibitory effect of dextran sulfate and heparin on replication of human immunodeficiency virus in vitro. Proc Natl Acad Sci U S A. 1988;85:6132-6136.
29. Baba M, Schols D, Pauwels R, Nakashima H, De Clercq E. Sulfated polysaccharides as potent inhibitors of HIV-induced syncytium formation: A new strategy towards AIDS chemotherapy. J Acquir Immune Defic Syndr. 1990;3:493-499.
30. Shaunak S, Gooderham NJ, Edwards RJ, et al. Infection by HIV-1 blocked by binding of dextrin 2-sulphate to the cell surface of activated human peripheral blood mononuclear cells and cultured T cells. Br J Pharmacol. 1994;113:151-158.
31. McClure MO, Moore JP, Blanc DF, et al. Investigations into the mechanism by which sulfated polysaccharides inhibit HIV infection in vitro. AIDS Res Hum Retroviruses. 1992;8:19-26.
32. Javan CM, Gooderham NJ, Edwards RJ, Davies DS, Shaunak S. Anti-HIV type 1 activity of sulfated derivatives of dextrin against primary viral isolates of HIV type 1 in lymphocytes and monocyte-derived macrophages. AIDS Res Hum Retroviruses. 1997;13:875-880.
33. Gupta P, Collins KB, Ratner D, et al. Memory CD4(+) T cells are the earliest detectable human immunodeficiency virus type 1 (HIV-1)-infected cells in the female genital mucosal tissue during HIV-1 transmission in an organ culture system. J Virol. 2002;76:9868-9876.
34. Moulard M, Lortat-Jacob H, Mondor I, et al. Selective interactions of polyanions with basic surfaces on human immunodeficiency virus type 1 gp120. J Virol. 2000;74:1948-1960.
35. Stafford MK, Cain D, Rosenstein I, et al. A placebo-controlled, double-blind prospective study in healthy female volunteers of dextrin sulphate gel: a novel potential intravaginal virucide. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;14:213-218.
36. Chapman A. Assessment of safety and tolerance of intravaginal dextrin sulphate gel in healthy volunteers. ML Laboratories PLC report MlfiD070-01, February 2000.
37. Low-Beer N, Gabe R, McCormack S, Kitchen VS, Lacey CJ, Nunn AJ. Dextrin sulfate as a vaginal microbicide: randomized, double-blind, placebo-controlled trial including healthy female volunteers and their male partners. J Acquir Immune Defic Syndr. 2002;31:391-398.
38. De Raucourt E, Mauray S, Chaubet F, Maiga-Revel O, Jozefowicz M, Fischer AM. Anticoagulant activity of dextran derivatives. J Biomed Mater Res. 1998;41:49-57.
39. Low-Beer N, Jespers V, McCormack S, et al. A safety study of dextrin sulphate gel as a novel vaginal microbicide: data from HIV negative and positive women [abstract]. Microbicides 2002 Meeting. Antwerp, Belgium (May 12-15, 2002). Abstract B-095.
40. Michael B, Pickering J, Mukwaya S, et al. A safety study of dextrin sulphate vaginal microbicide [abstract]. Microbicides 2004, March 28-31, 2004, Hilton, London Metropole. Abstract 02002.
41. Sangeeta S, Cowen M, Conder G, et al. Magnetic resonance imaging study of the distribution and retention of dextrin sulphate [abstract]. Microbicides 2004, March 28-31, 2004, Hilton, London Metropole. Abstract 02092,
42. Van Damme L, Jespers V, Van Dyck E, Chapman A. Penile application of dextrin sulphate gel (Emmelle). Contraception. 2002;66:133-136.
43. New Scientist.com HIV-blocking microbicides go on trial [press release]. March 23, 2004. Available at: http://www.newscientist.com/article.ns?id=dn4805. Accessed March 1, 2005.
44. ML Laboratories plc. ML Laboratories pic-Emmelle gel to enter into £16m research programme funded by important international collaboration to protect against AIDS [press release]. February 19,2002. Available at: http://www.mllabs.co.uk/2002.htm#10. Accessed March 1, 2005.
45. The Rockefeller Foundation. The economics of microbicide development. A report of the pharmaco-economic working group of the Rockefeller Foundation. Available at: http://www.rockfound.org/Documents/488/rep3_economics.pdf. Accessed March 1, 2005.
46. Kawamura T, Cohen SS, Borris DL, et al. Candidate microbicides block HIV-1 infection of human immature Langerhans cells within epithelial tissue explants. J Exp Med. 2000;192:1491-500.
47. Busso ME, Resnick L. Anti-human immunodeficiency virus effects of dextran sulfate are strain dependent and synergistic or antagonistic when dextran sulfate is given in combination with dideoxynucleosides. Antimicrob Agents Chemother. 1990;34:1991-1995.
48. Shaunak S, Thornton M, Teo I, Chandler B, Jones M, Steel S. Optimisation of the degree of sulfation of a polymer based construct to block the entry of HIV-1 into cells. J Drug Target. (2003);11:443-448.
49. Fisher AG, Ensoli B, Looney D, et al. Biologically diverse molecular variants within a single HIV-1 isolate. Nature. 1988;334:444-447.
50. Su SV, Gurney KB, Lee B. Sugar and spice: viral envelope-DC-SIGN interactions in HIV pathogenesis. Curr HIV Res. 2003;1:87-99.
51. Neyts J, Snoeck R, Schols D, et al. Sulfated polymers inhibit the interaction of human cytomegalovirus with cell surface heparin sulfate. Virology. 1992;189:48-58.